Summit Therapeutics (SMMT) Gross Profit (2017 - 2020)

Summit Therapeutics (SMMT) has 4 years of Gross Profit data on file, last reported at -$7.6 million in Q1 2020.

• Quarterly Gross Profit rose 4.49% year-over-year to -$7.6 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$68.5 million (down 2172.18% YoY) and the FY2019 annual result came in at -$32.6 million, changed N/A from the prior year.
• Gross Profit grew to -$7.6 million in Q1 2020, from -$43.6 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $32.6 million in Q3 2018 to a low of -$43.6 million in Q4 2019.
• A 4-year average of -$8.3 million and a median of -$7.9 million in 2019 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2018 — Gross Profit jumped 681.99% — and 2019, when it sank 123.93%.
• Tracing SMMT's Gross Profit over 4 years: stood at -$6.8 million in 2017, then plunged by 77.57% to -$12.1 million in 2018, then sank by 258.84% to -$43.6 million in 2019, then soared by 82.56% to -$7.6 million in 2020.
• The last three Gross Profit figures came in at -$7.6 million (Q1 2020), -$43.6 million (Q4 2019), and -$9.5 million (Q4 2019), per Business Quant data.